Breaking News! GeneRulor’s FrCas9 Wins Silver Prize at the 2025 Guangdong-Hong Kong-Macao Greater Bay Area High-Value Intellectual Property Competition

At the finals of the 2025 Guangdong-Hong Kong-Macao Greater Bay Area High-Value Intellectual Property Cultivation and Deployment Competition (the "Bay Area IP Competition"), GeneRulor stood out in the biomedicine and healthcare track with the commercialization project of its proprietary high-fidelity FrCas9 gene editing system, and was awarded the Silver Prize in the patent category!

This award represents strong recognition of the technological advancement and commercial value of the FrCas9 system, and it also marks a major breakthrough in China’s independent innovation in foundational gene editing tools, injecting new momentum into the high-quality development of the country’s biopharmaceutical industry.

About the Guangdong-Hong Kong-Macao Greater Bay Area High-Value Intellectual Property Cultivation and Deployment Competition

The Guangdong-Hong Kong-Macao Greater Bay Area High-Value Intellectual Property Cultivation and Deployment Competition is a national intellectual property event jointly hosted by the China National Intellectual Property Administration and the People’s Government of Guangdong Province. It is widely recognized as the most prestigious and influential intellectual property innovation and entrepreneurship competition in the Greater Bay Area. The competition focuses on strategic emerging industries and future-oriented industries, with the goal of identifying and cultivating high-quality projects distinguished by high-value patents, strong growth potential, and robust market competitiveness, thereby promoting the deep integration of intellectual property and industry.

This year’s competition attracted thousands of innovative projects from across the Greater Bay Area and throughout China. After multiple rounds of selection, only a limited number of projects advanced to the finals and received awards. GeneRulor’s success in such intense competition fully demonstrates the FrCas9 platform’s innovation strength, industrial value, and intellectual property quality.

Breaking Technical Barriers: Building China’s Homegrown “Gene Scissors”

For many years, conventional CRISPR-Cas9 systems have been constrained by bottlenecks such as high off-target risk and overseas patent monopolies, severely limiting China’s independent development and clinical application of gene editing technologies. In response to this industry challenge, GeneRulor has devoted years to the gene editing field and, through its proprietary streamlined novel CRISPR screening platform, successfully identified and optimized FrCas9, a novel type II-A editor derived from the murine gut bacterium Faecalibaculum rodentium.

Three Core Advantages of FrCas9

• Higher Editing Efficiency: AID-seq large-scale validation covering 1,825 sites showed that FrCas9 achieved an average on-target read count of 734.07, representing an increase of more than 124% over conventional SpCas9 and substantially improving the success rate of gene editing.

• Superior Editing Precision: Under the same conditions, FrCas9 exhibited an average of only 9.7 off-target sites, far below the 117.62 observed for SpCas9, reducing off-target risk by approximately 92% and significantly improving safety for clinical applications.

• Broader Targeting Scope: FrCas9 recognizes the NNTA PAM sequence. Compared with the NGG PAM recognized by SpCas9, this feature provides markedly greater targeting flexibility, enabling precise editing at a broader range of genomic loci and greatly expanding its utility in both basic research and therapeutic development.

Recognition by Leading International Journals

Research findings related to FrCas9 have been published in leading international journals including Nature Communications, Science Advances, and Cell Genomics, receiving broad recognition and strong acclaim from the global gene editing community. This not only demonstrates the scientific advancement of the FrCas9 platform but also provides a solid academic foundation for its industrial translation.

Global Applications and Cross-Species Validation of FrCas9

FrCas9 has not only achieved breakthroughs in fundamental research, but has also demonstrated outstanding versatility and stability in practical applications. To date, FrCas9 has been validated across multiple species and use scenarios:

• Applications in human cell lines: Efficient editing has been demonstrated in multiple human cell lines, including HEK293T, Jurkat, and K562, providing powerful tool support for gene therapy and disease model research.

• Model organism research: FrCas9 has been successfully applied to genome editing in model organisms such as mice and zebrafish, enabling the generation of precise animal models for disease mechanism studies and drug development.

• Agricultural breeding: FrCas9 has shown strong editing performance in important crops including rice and wheat, opening new avenues for crop improvement and trait optimization.

• Industrial microorganism engineering: FrCas9 has been applied to metabolic engineering in industrial strains such as yeast and Escherichia coli, improving the efficiency and yield of biomanufacturing.

Across different species, FrCas9 consistently demonstrates high efficiency, high precision, and low off-target activity, fully validating its substantial potential as a universal gene editing platform and earning broad adoption and recognition among international peers.

Continuous Innovation: From a Natural Protein to Upgraded Editors

GeneRulor has not stopped at the strong performance of native FrCas9. Instead, it has continued to drive iterative upgrades and functional expansion, building a comprehensive FrCas9 technology product matrix:

Upgraded eFrCas9: An Ideal Balance Between Efficiency and Fidelity

Based on cryo-EM structural analysis, the team developed eFrCas9, an upgraded editor. While maintaining high fidelity, eFrCas9 delivers an approximately two-fold increase in editing efficiency and is compatible with base editing and prime editing. These capabilities further expand its utility in precision medicine and provide stronger technical support for applications such as rare disease treatment and cancer immunotherapy.

TREX2-FrCas9 Fusion Protein: A New Breakthrough in Clinical Safety

To further improve clinical safety, the team successfully constructed the TREX2-FrCas9 fusion protein. This innovative design can significantly reduce the risk of editing-induced chromosomal translocations, providing a higher level of safety assurance for gene therapy and moving the FrCas9 platform another major step closer to clinical application.

Driving Translation: A Full-Chain Layout from the Laboratory to Industrialization

Global Intellectual Property Protection Framework

Behind this award lies GeneRulor’s sustained investment in intellectual property strategy and technology iteration. To date, the FrCas9 system has received patent grants in China, the United States, Australia, Russia, and Macao, China. GeneRulor holds exclusive global rights to this system and has established a comprehensive intellectual property protection framework, providing solid support for the global promotion and commercialization of FrCas9 technology.

End-to-End Industrialization Capability

The company has established an ISO 9001 quality management system and possesses end-to-end capabilities spanning tool development, large-scale manufacturing, and support for investigational new drug (IND) filings. The FrCas9 system is applied not only in the company’s internal new drug development pipeline, but also through licensing collaborations with multiple well-known institutions in China and abroad. Its application scenarios include:

• Basic scientific research: gene function studies and exploration of disease mechanisms

• Cell and gene therapy: cancer immunotherapy, rare disease treatment, and correction of inherited disorders

• Crop breeding: trait improvement, stress-resilient breeding, and nutritional enhancement

• In vitro diagnostics: development of molecular diagnostic tools and construction of disease detection platforms

Looking Ahead: Advancing Gene Editing Technology Together

In 2023, Casgevy, the world’s first CRISPR-based gene editing therapy, received marketing approval, marking the arrival of a golden era for gene therapy. GeneRulor’s Silver Prize in the Bay Area IP Competition further demonstrates that its self-developed FrCas9 gene editing platform is gaining increasingly broad recognition on the strength of high-value intellectual property and outstanding technical performance.

Looking to the future, GeneRulor will continue to deepen the development and application of the FrCas9 technology family, with the goal of providing global research institutions and biopharmaceutical companies with safer, more efficient, and independently controlled gene editing solutions. We sincerely invite domestic and international partners to work with us to advance innovation and application in gene therapy and make greater contributions to human health.

━━━━━━━━━━━━━━━━━━━━

GeneRulor Core Tool Enzyme Products

While continuing to deepen its foundational technology capabilities, GeneRulor has also translated these innovations into stable and reliable research tools. We maintain ready stock of a full portfolio of high-quality tool enzymes covering CRISPR gene editing, base editing, and prime editing, helping accelerate your research and translational progress!

★ FrCas9 Series (GeneRulor Proprietary Intellectual Property)

• FrCas9 Nuclease | Cat. No.: GR100701 / GR100702 / GR100703 | Pack Size: 100 / 500 / 2500 pmol

• eFrCas9 Nuclease | Cat. No.: GR100801 / GR100802 / GR100803 | Pack Size: 100 / 500 / 2500 pmol

• TREX2-FrCas9 Nuclease | Cat. No.: GR100901 / GR100902 | Pack Size: 500 / 2500 pmol

Other CRISPR Tool Enzymes

• SpCas9 Series: SpCas9 Nuclease, SpCas9-sfGFP, nCas9(D10A)-sfGFP

• Cas12 Series: LbCas12a, AsCas12a, and LtCas12a nucleases

• Other Editors: SaCas9, IscB, and openCRISPR nucleases

• Functional Proteins: dCas9-VP64, MS2-p65-HSF1, and dPspCas13b-ADAT2

━━━━━━━━━━━━━━━━━━━━

Partnership Opportunities

Patent Licensing | Strategic Collaboration | Pipeline Development

We welcome your inquiries and look forward to building the future of gene editing together!